MARC 主機 00000cam 2200481 i 4500
001 1348934408
003 OCoLC
005 20221214034126.0
006 m o d
007 cr cnu---unuuu
008 221027s2022 mau o 000 0 eng d
020 9780323903899
035 (OCoLC)1348934408
040 OPELS|beng|erda|epn|cOPELS|dEBLCP|dOCLCF|dAS
050 4 RC268.45
082 04 616.9940654|223
245 00 Nutrition and cancer /|cEdited by Aitziber Buqu⥬ Lorenzo
Galluzzi
264 1 Cambridge, MA :|bAcademic Press,|c2022
300 1 online resource
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
490 1 International review of cell and molecular biology ;
|vvolume 373
505 0 Intro -- Nutrition and Cancer -- Copyright -- Contents --
Contributors -- Emergent impact of lifestyle on tumor
progression and response to therapy -- Acknowledgments --
Conflict of interest -- References -- Chapter One:
Modifying dietary amino acids in cancer patients -- 1.
Introduction -- 2. Reducing availability of NEAAs as an
anti-cancer approach -- 3. Role of essential AAs in cancer
biology -- 4. Altering dietary protein to limit tumor
growth and enhance cancer therapy -- 5. Role of bacteria
in mediating the pro-tumorigenic effects of dietary AAs
505 8 6. Current recommendations for protein intake in cancer
patients -- 7. Considerations for evaluating the impact of
modifying AA intake on treatment response and outcomes in
patients with cancer -- Acknowledgments -- Conflicts of
interest -- References -- Chapter Two: Targeting amino
acid metabolism in cancer -- 1. Introduction -- 2.
Asparagine -- 2.1. Asparagine synthetase (ASNS) -- 2.1.1.
Catalytic function and structure of ASNS -- 2.1.2. ASNS
deficiency -- 2.1.3. ASNS regulation -- 2.2. L-
asparaginase (ASNase) -- 2.2.1. ASNase in leukemias and
lymphomas -- 2.2.2. ASNase in solid tumors
505 8 2.2.3. Glutaminase activity of ASNase -- 2.2.4. Limits of
the ASNase therapy -- 3. Arginine -- 3.1. Metabolism of
arginine -- 3.2. Arginine-nitric oxide pathway -- 3.3.
Arginine-ornithine-polyamine pathway -- 3.4. Suitable
candidates for arginine-depleting enzyme therapies -- 3.5.
Arginine deiminase -- 3.5.1. Arginine deiminase-based
therapy -- 3.5.2. Limitations of arginine deiminase
therapy -- 3.6. Arginase -- 3.6.1. Arginase therapy --
3.6.2. Limitations of arginase therapy -- 4. Methionine --
4.1. Methionine metabolism -- 4.2. The Hoffman effect --
4.3. Methioninase
505 8 4.3.1. Methioninase therapy -- 5. Cysteine -- 5.1.
Cysteine metabolism -- 5.2. Cyst(e)inase -- 5.2.1.
Cyst(e)inase therapy -- 6. Concluding remarks --
Acknowledgments -- References -- Chapter Three: Fasting
and cancer: from yeast to mammals -- 1. Introduction -- 2.
Calorie restriction -- 3. Fasting and fasting mimicking
diets -- 4. Fasting mimicking diets and cancer -- 4.1.
Differential stress resistance -- 4.2. Differential stress
sensitization -- 4.3. FMD and antitumor immunity -- 5.
Fasting-mimicking diets and non-toxic interventions to
kill cancer cells
505 8 5.1. FMD synergizes with high-dose vitamin C to kill KRAS-
mutant cancer cells -- 5.2. FMD cycles potentiate hormone
therapies and induce breast cancer regression -- 6.
Fasting-mimicking diets in clinical oncology --
Acknowledgments -- References -- Chapter Four: Fasting and
cancer responses to therapy -- 1. Introduction -- 2.
Nutrients restriction in rodents and humans -- 3. Calorie
restriction in cancer therapy -- 4. Alternative approaches
to fasting and CR in cancer therapy -- 5. Conclusion --
Acknowledgments -- Conflicts of interest -- Authors
contribution -- References
588 0 Print version record
650 0 Cancer|xNutritional aspects
650 0 Cancer|xCytopathology
650 7 Cancer|xCytopathology.|2fast|0(OCoLC)fst00845344
650 7 Cancer|xNutritional aspects.|2fast|0(OCoLC)fst00845407
655 0 Electronic books
700 1 Buqu⥬ Aitziber,|eeditor
700 1 Galluzzi, Lorenzo,|eeditor
776 08 |iPrint version:|tNUTRITION AND CANCER.|d[Place of
publication not identified] : ELSEVIER ACADEMIC PRESS,
2022|z0323903886|w(OCoLC)1273677495
830 0 International review of cell and molecular biology ;|vv.
373
856 40 |uhttps://www.sciencedirect.com/science/bookseries/
19376448/373|zeBook(ScienceDirect)
